Looming "patent cliff" drives a surge in drugmaker M&A

11/14/2010 | Philadelphia Inquirer, The

A recent wave of mergers and acquisitions in the drug industry was largely driven by impending revenue loss from a "patent cliff," experts said. "Over the next five years, the pharmaceutical industry will face the sharpest revenue decline in history," according to a December report by Bernstein Research. "Of the top 10 biggest drugs in the world, nine will lose patent protection; of the top 20, 18 will lose protection."

View Full Article in:

Philadelphia Inquirer, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX